MPLT
MapLight Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$13.77
+4.79%Aug 13, 2026, 20:05 UTC
MapLight Therapeutics reported financial results for the second quarter ended June 30, 2026, ending the quarter with $351.3 million in cash, cash equivalents and investments.
Source:Aug 13, 2026, 20:05 UTC
MapLight Therapeutics reported Phase 2 IRIS results for ML-004 in autism spectrum disorder, with clinically meaningful improvements in irritability observed in a prespecified adolescent subgroup.
Source:Aug 13, 2026, 13:10 UTC
MapLight Therapeutics announced a private placement financing (PIPE) to raise approximately $150 million in gross proceeds from institutional and accredited investors.
Source:Aug 13, 2026, 00:00 UTC
MapLight Therapeutics, Inc. signed a private placement financing agreement to raise approximately $150 million through the sale of common stock and pre-funded warrants.
Jul 27, 2026, 12:30 UTC
MapLight Therapeutics announced that its schizophrenia drug failed to show statistically significant symptom improvement in the once-daily dosing arm of a mid-stage trial.
Jul 27, 2026, 11:00 UTC
MapLight Therapeutics announced positive topline results from its Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, meeting the primary endpoint with statistical significance.
Jun 22, 2026, 11:00 UTC
MapLight Therapeutics announced topline results from its Phase 2 IRIS study of ML-004 in autism spectrum disorder.